PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

BACKGROUND: Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabian, Kellsye P, Padget, Michelle R, Donahue, Renee N., Solocinski, Kristen, Robbins, Yvette, Allen, Clint T., Lee, John H., Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Schlom, Jeffrey, Hodge, James W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247398/
https://www.ncbi.nlm.nih.gov/pubmed/32439799
http://dx.doi.org/10.1136/jitc-2019-000450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247398/
https://www.ncbi.nlm.nih.gov/pubmed/32439799
http://dx.doi.org/10.1136/jitc-2019-000450

Ejemplares similares